Jiang, Tao
Chen, Jianhua
Xu, Xingxiang
Cheng, Ying
Chen, Gongyan
Pan, Yueyin
Fang, Yong
Wang, Qiming
Huang, Yunchao
Yao, Wenxiu
Wang, Rui
Li, Xingya
Zhang, Wei
Zhang, Yanjun
Hu, Sheng
Guo, Renhua
Shi, Jianhua
Wang, Zhiwu
Cao, Peiguo
Wang, Donglin
Fang, Jian
Luo, Hui
Geng, Yi
Xing, Chunyan
Lv, Dongqing
Zhang, Yiping
Yu, Junyan
Cang, Shundong
Zhang, Yaxi
Zhang, Jiao
Yang, Zeyu
Shi, Wei
Zou, Jianjun
Zhou, Caicun http://orcid.org/0000-0002-1072-9941
Ren, Shengxiang
Funding for this research was provided by:
National Natural Science Foundation of China (81871865)
Article History
Received: 18 September 2021
Accepted: 6 December 2021
First Online: 3 January 2022
Declarations
:
: The clinical protocol was approved by the respective institutional review boards and ethics committees. All participants provided written informed consent.
: Not applicable.
: CZ reported honoraria as a speaker from Roche, Lily China, Boehringer Ingelheim, Merck, Hengrui, Qilu, Sanofi, Merck Sharp & Dohme, Innovent Biologics, C-Stone, Luye Pharma, TopAlliance Biosciences, and Amoy Diagnositics; and advisor fees for Innovent Biologics, Hengrui, Qilu, and TopAlliance Biosciences. SR reported honoraria as a speaker from Boehringer Ingelheim, Lilly, Merck Sharp & Dohme, Roche, Hengrui, and Junshi, advisor fees for Roche, Merck Sharp & Dohme, and Boehringer Ingelheim and research funding from Hengrui. ZY, WS and JZ were employees of Hengrui. No other disclosures were reported.